Loading…
vTv Therapeutics Inc. is projected to rise to $36.74 by 2027, a +14% move from its current price of $32.35. VTVT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $31.59 | $32.37 | $33.17 | +0.06% |
| Aug 5 | $31.28 | $32.39 | $33.53 | +0.11% |
| Aug 6 | $31.06 | $32.40 | $33.81 | +0.17% |
| Aug 7 | $30.87 | $32.42 | $34.05 | +0.22% |
| Aug 8 | $30.71 | $32.44 | $34.26 | +0.28% |
| Aug 9 | $30.57 | $32.46 | $34.46 | +0.33% |
| Aug 10 | $30.44 | $32.48 | $34.65 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.44 | $32.48 | $34.65 | +0.39% |
| Week 2 | $29.75 | $32.60 | $35.73 | +0.78% |
| Week 3 | $29.26 | $32.73 | $36.61 | +1.16% |
| Week 4 | $28.86 | $32.85 | $37.39 | +1.56% |
| Week 5 | $28.54 | $32.98 | $38.12 | +1.95% |
| Week 6 | $28.25 | $33.11 | $38.80 | +2.34% |
| Week 7 | $28.00 | $33.24 | $39.45 | +2.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
vTv Therapeutics Inc. is a late-stage biopharmaceutical company that focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Incorporated in 2015 and headquartered in High Point, North Carolina, the company operates in the Healthcare sector and seeks to advance therapies across multiple indications for chronic diseases.
vTv Therapeutics Inc. (VTVT) is currently trading at $32.29 with a market capitalization of $127.18M and a rank of 4002. The stock’s price outlook, based on the year-by-year forecast, shows a return to growth after a flat-to-modest start in 2026, rising through the decade with rising average prices and increasingly positive ROIs.
The forecast emphasizes a bullish trajectory later in the period, culminating in substantial upside by 2050.
A major floor 17.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.0% below — buyers have tended to step in here.
The nearest ceiling, 16.4% above — a clean break opens room to run.
A major ceiling 27.3% above — clearing it would confirm fresh momentum.
Key VTVT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTVT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $31.72 | Buy | $31.99 | Buy |
| MA 10 | $31.80 | Buy | $32.01 | Buy |
| MA 20 | $32.48 | Sell | $32.46 | Sell |
| MA 50 | $33.42 | Sell | $33.28 | Sell |
| MA 100 | $34.54 | Sell | $33.56 | Sell |
| MA 200 | $33.27 | Sell | $31.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.05 | Neutral |
| Stoch RSI (14) | 84.91 | Sell |
| CCI (20) | -9.15 | Neutral |
| Williams %R (14) | -25.69 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -1.04 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 74.31 | Neutral |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -1.76 | Sell |
| Ultimate (7,14,28) | 56.99 | Neutral |
| Momentum (10) | -0.53 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 32.11 | Buy |
| ADX (14) | 10.82 | Neutral |
| ATR (14) | 0.73 | Info |
Technical sentiment is NEUTRAL. The RSI(14) sits at 40, indicating neither overbought nor oversold conditions. The 50-day simple moving average is $33.72 and the 200-day simple moving average is $32.77, with near-term support at $30.44 and resistance at $37.65.
The 30-day trading range spans from a low of $26.54 to a high of $39.28, highlighting a broad but contained movement around the current level. Annualized volatility is high at 60%, signaling elevated risk alongside the potential for outsized moves within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.02 | $32.35 | $41.75 | 0% | Neutral | |
| $29.59 | $36.74 | $48.07 | +14% | Neutral | |
| $28.30 | $36.04 | $48.78 | +11% | Neutral | |
| $31.78 | $41.32 | $57.45 | +28% | Bullish | |
| $36.08 | $47.76 | $67.92 | +48% | Bullish | |
| $39.88 | $53.67 | $77.83 | +66% | Bullish | |
| $45.80 | $62.58 | $92.35 | +93% | Bullish | |
| $47.61 | $66.00 | $98.96 | +104% | Bullish | |
| $47.83 | $67.20 | $102.26 | +108% | Bullish | |
| $49.54 | $70.50 | $108.75 | +118% | Bullish | |
| $72.11 | $108.78 | $177.68 | +236% | Bullish | |
| $128.76 | $214.44 | $380.87 | +563% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $29.02 | $32.35 | $38.94 | +0.00% |
| September 2026 | $28.63 | $33.76 | $40.85 | +4.36% |
| October 2026 | $28.68 | $34.02 | $41.56 | +0.76% |
| November 2026 | $28.01 | $33.40 | $41.12 | -1.83% |
| December 2026 | $28.11 | $33.67 | $41.75 | +0.81% |
Click any year to see its month-by-month VTVT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VTVT is projected to trade between $29.02 and $41.75, averaging $32.35 — a potential gain of 0% from today's $32.35. A consolidation phase looks the most probable path here.
vTv Therapeutics Inc.'s 2027 outlook centres on $36.74, within a $29.59 to $48.07 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2028, VTVT could reach as high as $48.78, with a base case around $36.04 and support toward $28.30 — roughly +11% from $32.35. A consolidation phase looks the most probable path here.
Expect VTVT to range from $31.78 to $57.45 through 2029. The $41.32 average target implies a +28% move from current prices. That is up +15% on the projected 2028 average. Momentum favours further upside here.
The VTVT price prediction for 2030 points to an average of $47.76 (low $36.08, high $67.92) — a potential gain of +48% on today's $32.35. Buyers look set to stay in control over this stretch.
In 2031, VTVT is projected to trade between $39.88 and $77.83, averaging $53.67 — a potential gain of +66% from today's $32.35. That is up +12% on the projected 2030 average. Momentum favours further upside here.
vTv Therapeutics Inc.'s 2032 outlook centres on $62.58, within a $45.80 to $92.35 range. That is up +17% on the projected 2031 average. That marks a +93% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, VTVT could reach as high as $98.96, with a base case around $66.00 and support toward $47.61 — roughly +104% from $32.35. Momentum favours further upside here.
Expect VTVT to range from $47.83 to $102.26 through 2034. The $67.20 average target implies a +108% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The VTVT price prediction for 2035 points to an average of $70.50 (low $49.54, high $108.75) — a potential gain of +118% on today's $32.35. Momentum favours further upside here.
In 2040, VTVT is projected to trade between $72.11 and $177.68, averaging $108.78 — a potential gain of +236% from today's $32.35. That is up +54% on the projected 2035 average. Buyers look set to stay in control over this stretch.
vTv Therapeutics Inc.'s 2050 outlook centres on $214.44, within a $128.76 to $380.87 range. That is up +97% on the projected 2040 average. That marks a +563% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VTVT today (≈ 30.911901 VTVT) could be worth
$6,628.73
+$5,628.73 (+563%) by 2050 · US Dollar
Based on the average projected VTVT price of $214.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTVTwould be worth at today's price.
$1,000 invested in VTVT on Jul 31, 2025 (≈ 66.889633 VTVT) would be worth
$2,163.88
+$1,163.88 (+116.4%) today · 2.16× · US Dollar
Based on a VTVT entry price of $14.95 vs. today's $32.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.73 | $1,052.72 | +5.3% |
| 1 month ago | $35.05 | $922.97 | -7.7% |
| 3 months ago | $31.68 | $1,020.99 | +2.1% |
| 6 months ago | $38.31 | $844.43 | -15.6% |
| 1 year ago | $14.95 | $2,163.88 | +116.4% |
| All time (5.0y) ago | $78.4 | $412.63 | -58.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTVT forecast.
Our base-case forecast reaches $65.00 around 2033.
Implied market cap at $65.00: $256.01M
The multi-year forecast shows a clear bullish tilt after 2026. In 2026 the average price is $32.29 with a min of $29.02 and a max of $42.85 and 0% ROI, signaling a stable start. By 2027 the average edges higher to $35.98 (min $28.42, max $48.32) with a 11.4% ROI, and 2028 sees an average of $34.90 (min $26.74, max $48.78) with an 8.1% ROI.
2029 strengthens to an avg of $41.14 and 27.4% ROI, followed by 2030 at $46.75 avg with a max of $69.18 and a 44.8% ROI, continuing the bullish trend.
From 2031 onward, the forecast remains bullish with 2031 avg $52.89 (max $80.07, ROI 63.8%), 2032 avg $64.04 (max $98.94, ROI 98.3%), and 2033 avg $65.37 (max $102.87, ROI 102.4%). The trajectory holds into 2034–2035 with continued upside (2034 avg $65.14, max $104.26, ROI 101.7%; 2035 avg $69.90, max $113.65, ROI 116.5%). By 2040 the average rises to $107.71 (min $66.56, max $186.99) with a 233.6% ROI, and by 2050 the average is $215.62 (min $116.92, max $411.65) delivering a 567.8% ROI, with overall sentiment remaining BULLISH.
These figures illustrate an upward long-term trajectory, recognizing that actual results will depend on multiple unpredictable factors and are not guaranteed.
Tap a question to reveal the answer.
In 2030 the forecast shows min $34.13, avg $46.75, max $69.18 with a 44.8% ROI and a BULLISH sentiment.
Forecasts show a bullish trajectory from 2029 onward, with 2029 avg $41.14 (ROI 27.4%), 2030 ROI 44.8%, 2031 ROI 63.8%, 2032 ROI 98.3%, 2033 ROI 102.4%, 2034 ROI 101.7%, 2035 ROI 116.5%, 2040 ROI 233.6%, and 2050 ROI 567.8%.
Yes. The 2033 max is $102.87, indicating a potential to exceed $100, with the 2032 max $98.94 and the 2033 max $102.87.
For 2040 the forecast shows min $66.56, avg $107.71, max $186.99 with a 233.6% ROI and a BULLISH sentiment.
Current price is $32.29 and market cap is $127.18M, with a rank of 4002.
vTv Therapeutics Inc. Community Discussion
0Share your vTv Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.